The VP1-unique region of parvovirus B19 induces myocardial injury in mice

References

• Escher F, Modrow S, Sabi T, Kühl U, Lassner D, Schultheiss HP, . Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 2008;14:CR589–97.
   PubMed Web of Science ®Google Scholar
• Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, . Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol 2009;44:27–32.
   PubMed Web of Science ®Google Scholar
• Savarese I, De Carolis MP, Costa S, De Rosa G, De Carolis S, Lacerenza S, . Atypical manifestations of congenital parvovirus B19 infection. Eur J Pediatr 2008;167:1463–6.
   PubMed Web of Science ®Google Scholar
• Dennert R, Schalla S, Suylen RJ, Eurlings L, Heymans S. Giant cell myocarditis triggered by a parvovirus B19 infection. Int J Cardiol 2009;134:115–6.
   PubMed Web of Science ®Google Scholar
• Maisch B, Ristic AD, Portig I, Pankuweit S. Human viral cardiomyopathy. Front Biosci 2003;8:39–67.
   PubMed Web of Science ®Google Scholar
• Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, . Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581–90.
   PubMed Web of Science ®Google Scholar
• Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, . Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965–70.
   PubMed Web of Science ®Google Scholar
• Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, . The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. JVirol 2002;76:2014–8.
   PubMed Web of Science ®Google Scholar
• Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1:72–73.
   PubMed Web of Science ®Google Scholar
• Lu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006;193:582–90.
   PubMed Web of Science ®Google Scholar
• Zadori Z, Szelei J, Lacoste MC, Li Y, Gariépy S, Raymond P, . A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001;1:291–302.
   PubMed Web of Science ®Google Scholar
• Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, . VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008;374:444–52.
   PubMed Web of Science ®Google Scholar
• Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, . Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 1992;89:2023–9.
   PubMed Web of Science ®Google Scholar
• Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, . Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 1999;73:1974–9.
   PubMed Web of Science ®Google Scholar
• Corcoran A, Doyle S, Waldron D, Nicholson A, Mahon BP. Impaired gamma interferon responses against parvovirus B19 by recently infected children. JVirol 2000;74:9903–10.
   PubMed Web of Science ®Google Scholar
• Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. JVirol 2006;80:12017–24.
   PubMed Web of Science ®Google Scholar
• Escher F, Kuhl U, Sabi T, Suckau L, Lassner D, Poller W, . Immunohistological detection of parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. Med Sci Monit 2008;14:CR333–8.
   PubMed Web of Science ®Google Scholar
• Seishima M, Shibuya Y, Suzuki S, Arakawa C. Acute heart failure associated with human parvovirus B19 infection. Clin Exp Dermatol 2008;33:588–90.
   PubMed Web of Science ®Google Scholar
• Donal E, Piriou N, Nanadoumgar H, Mignot A, Bressolette C, Toquet C, . Viral cardiomyopathy. Arch Mal Coeur Vaiss 2005;98:984–91.
   PubMedGoogle Scholar
• Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 2004;193:101–7.
   PubMed Web of Science ®Google Scholar
• Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586–97.
   PubMed Web of Science ®Google Scholar
• Hood D, Van Lente F, Estes M. Serum enzyme alterations in chronic muscle disease. A biopsy-based diagnostic assessment. Am J Clin Pathol 1991;95:402–7.
   PubMed Web of Science ®Google Scholar
• Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 1994;20:845–56.
   PubMed Web of Science ®Google Scholar
• Wu AH. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. Ann Clin Lab Sci 1999;29:18–23.
   PubMed Web of Science ®Google Scholar
• Takagi Y, Yasuhara T, Gomi K. Creatine kinase and its isozymes. Rinsho Byori 2001;(Suppl 116):52–61.
   PubMedGoogle Scholar
• Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC. The association of VP1 unique region protein in acute parvovirus B19 infection and antiphospholipid antibody production. Clin Chim Acta 2007;378:59–65.
   PubMed Web of Science ®Google Scholar
• Tzang BS, Tsai CC, Chiu CC, Shi JY, Hsu TC. Up-regulation of adhesion molecule expression and induction of TNF-α on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta 2008;395:77–83.
   PubMed Web of Science ®Google Scholar